Company Filing History:
3 out of 94 
2 out of 15 Years Active: 2022-2025
Title: **The Innovations of Young Bong Park: A Pioneer in Bispecific Antibodies**
Introduction
Young Bong Park, an inventive mind located in Yongin-si, South Korea, has made significant contributions to the field of biopharmaceuticals. With a portfolio of three patents, he is recognized for his innovative approach to developing bispecific antibodies aimed at treating cancer.
Latest Patents
Among Park's latest contributions is the patent for an "Anti-HER2/anti-4-1BB bispecific antibody and use thereof." This invention provides a unique therapeutic approach by offering both an anti-4-1BB and an anti-HER2 bispecific antibody, along with a pharmaceutical composition and a method for treating and/or preventing cancer. Additionally, he has developed an "Anti-EGFR/anti-4-1BB bispecific antibody," which similarly serves to treat cancer through the innovative use of bispecific antibodies.
Career Highlights
Throughout his career, Young Bong Park has been associated with reputable companies in the pharmaceutical sector, including Yuhan Corporation and Abl Bio Inc. His work at these organizations has allowed him to pioneer research and development efforts in innovative cancer treatments.
Collaborations
Park has collaborated with notable coworkers such as Na Rae Lee and Moo Young Song. These partnerships have been instrumental in advancing his research and enhancing the potential impact of his inventions on cancer therapies.
Conclusion
Young Bong Park's inventive spirit and his dedication to developing bispecific antibodies have made notable strides in the fight against cancer. His contributions not only add to the body of patents in the field but also hold the promise of tangible benefits for patients battling cancer. His work exemplifies the importance of innovation in the pharmaceutical industry and the vital role of inventors in shaping the future of medical treatments.